AnaCardio secured a €62.5 million ($70.5 million) Series B round to fund Phase IIb development of AC01, an oral calcium-sensitizing contractile agent for chronic advanced heart failure with reduced ejection fraction (HFrEF). The company says it will use the capital to fully fund advancement through Phase IIb and toward Phase III readiness by 2028. AnaCardio described AC01 as a differentiated pathway therapy originally in-licensed from Helsinn in 2022. The company cited encouraging Phase Ib/IIa results published in The Lancet and said it received positive scientific advice from both the FDA and EMA. The financing was co-led by Novo Holdings and the Ljungström family office, with participation from existing backers and new investor Innovestor Life Science. For the heart failure market, the round signals sustained appetite for oral, mechanism-distinct approaches as competitors refine late-stage strategies in a crowded HFrEF landscape.